{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:57:37Z","timestamp":1781697457438,"version":"3.54.5"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["CAN 2023 \/2807"],"award-info":[{"award-number":["CAN 2023 \/2807"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["22 1973 Pj 01 H"],"award-info":[{"award-number":["22 1973 Pj 01 H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012558","name":"Research and development Skane","doi-asserted-by":"publisher","award":["REGSKANE-622351"],"award-info":[{"award-number":["REGSKANE-622351"]}],"id":[{"id":"10.13039\/100012558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-00859"],"award-info":[{"award-number":["2021-00859"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5nes universitetssjukhus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018327","name":"Lantm\u00e4nnens Forskningsstiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6bergstiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009770","name":"Maud och Birger Gustavssons Stiftelser","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006738","name":"Lund University Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Mrs Berta Kamprad Foundation for Research and Combating Cancer Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.modpat.2026.100997","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:53:16Z","timestamp":1775260396000},"page":"100997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3317-865X","authenticated-orcid":false,"given":"Pontus","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Aramend\u00eda","family":"Cotillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Adam","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymeric","family":"Zadoroznyj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfrid","family":"Sj\u00f6dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Edsj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Heidenblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.modpat.2026.100997_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-471942","article-title":"New treatment options for non-muscle-invasive bladder cancer","volume":"45","author":"Filon","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.modpat.2026.100997_bib2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib3","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1097\/PAS.0000000000002053","article-title":"International Society of Urological Pathology Consensus Conference on current issues in bladder cancer. Working group 4: molecular subtypes of bladder cancer\u2014principles of classification and emerging clinical utility","volume":"48","author":"Warrick","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2026.100997_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","article-title":"A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma","volume":"68","author":"Patschan","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib5","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","article-title":"Basal\/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial","volume":"36","author":"Groeneveld","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2026.100997_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2026.01.003","article-title":"Prognostic factors for overall survival in the VESPER Trial: basal molecular subtype is a relevant key factor","author":"Pfister","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2026.100997_bib8","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","article-title":"Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade","volume":"42","author":"Hamidi","year":"2024","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.modpat.2026.100997_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-220124","article-title":"What is a bladder cancer molecular subtype?","volume":"9","author":"H\u00f6glund","year":"2023","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J Pathol"},{"key":"10.1016\/j.modpat.2026.100997_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.modpat.2026.100997_bib12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jmoldx.2022.05.006","article-title":"The Lund molecular taxonomy applied to non-muscle-invasive urothelial carcinoma","volume":"24","author":"Marzouka","year":"2022","journal-title":"J Mol Diagn"},{"issue":"12","key":"10.1016\/j.modpat.2026.100997_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jmoldx.2024.08.005","article-title":"A versatile and upgraded version of the LundTax classification algorithm applied to independent cohorts","volume":"26","author":"Cotillas","year":"2024","journal-title":"J Mol Diagn"},{"issue":"4","key":"10.1016\/j.modpat.2026.100997_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/path.6062","article-title":"The Lund taxonomy for bladder cancer classification\u2014from gene expression clustering to cancer cell molecular phenotypes, and back again","volume":"259","author":"H\u00f6glund","year":"2023","journal-title":"J Pathol"},{"issue":"1-6","key":"10.1016\/j.modpat.2026.100997_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/21681805.2022.2159519","article-title":"UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice\u2014from biobank to RNA-sequencing in real time","volume":"57","author":"Liedberg","year":"2023","journal-title":"Scand J Urol"},{"issue":"3","key":"10.1016\/j.modpat.2026.100997_bib16","article-title":"ComBat-seq: batch effect adjustment for RNA-seq count data","volume":"2","author":"Zhang","year":"2020","journal-title":"NAR Genom Bioinform"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12859-018-2246-7","article-title":"Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons","volume":"19","author":"Smid","year":"2018","journal-title":"BMC Bioinformatics"},{"issue":"18","key":"10.1016\/j.modpat.2026.100997_bib18","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1093\/bioinformatics\/btab088","article-title":"multiclassPairs: an R package to train multiclass pair-based classifier","volume":"37","author":"Marzouka","year":"2021","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.modpat.2026.100997_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/bioinformatics\/btu622","article-title":"switchBox: an R package for k-Top Scoring Pairs classifier development","volume":"31","author":"Afsari","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.modpat.2026.100997_bib20","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"issue":"8","key":"10.1016\/j.modpat.2026.100997_bib23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2022.07.006","article-title":"Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes","volume":"40","author":"Zaitsev","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of tumor infiltrating leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41467-022-28020-5","article-title":"Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data","volume":"13","author":"Danaher","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.modpat.2026.100997_bib26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100997_bib27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/bioinformatics\/btab763","article-title":"A comparison of rule-based and centroid single-sample multiclass predictors for transcriptomic classification","volume":"38","author":"Eriksson","year":"2022","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v077.i01","article-title":"Ranger: a fast implementation of random forests for high dimensional data in C++ and R","volume":"77","author":"Wright","year":"2017","journal-title":"J Stat Softw"},{"issue":"3","key":"10.1016\/j.modpat.2026.100997_bib30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13104-025-07138-x","article-title":"The importance of data transformation in RNA-seq preprocessing for bladder cancer subtyping","volume":"18","author":"Acedo-Terrades","year":"2025","journal-title":"BMC Res Notes"},{"issue":"4","key":"10.1016\/j.modpat.2026.100997_bib33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.modpat.2026.100997_bib34","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications","volume":"22","author":"Amin","year":"2009","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2026.100997_bib35","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib36","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/s41467-019-09990-5","article-title":"Complete deconvolution of cellular mixtures based on linearity of transcriptional signatures","volume":"10","author":"Zaitsev","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.modpat.2026.100997_bib37","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","article-title":"Impact of genetic polymorphisms on human immune cell gene expression","volume":"175","author":"Schmiedel","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.modpat.2026.100997_bib38","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","article-title":"RNA-seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types","volume":"26","author":"Monaco","year":"2019","journal-title":"Cell Rep"},{"issue":"31","key":"10.1016\/j.modpat.2026.100997_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2169","article-title":"A single-cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci Adv"},{"issue":"6472","key":"10.1016\/j.modpat.2026.100997_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax9198","article-title":"A genome-wide transcriptomic analysis of protein-coding genes in human blood cells","volume":"366","author":"Uhlen","year":"2019","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.modpat.2026.100997_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cjp2.245","article-title":"Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer","volume":"8","author":"Jackson","year":"2022","journal-title":"J Pathol Clin Res"},{"issue":"12","key":"10.1016\/j.modpat.2026.100997_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064898","article-title":"Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0","volume":"12","author":"H\u00e4ggstr\u00f6m","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.modpat.2026.100997_bib43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/JU.0000000000004542","article-title":"Hybrid 3-tier bladder cancer grade: the mutually beneficial marriage of 2 grading systems","volume":"214","author":"Kamat","year":"2025","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.modpat.2026.100997_bib44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100997_bib45","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.eururo.2012.05.063","article-title":"The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading","volume":"62","author":"Liedberg","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib46","first-page":"32","article-title":"News in the classification of WHO 2022 bladder tumors","volume":"115","author":"Raspollini","year":"2022","journal-title":"Pathologica"},{"issue":"3","key":"10.1016\/j.modpat.2026.100997_bib47","doi-asserted-by":"crossref","first-page":"110.e1","DOI":"10.1016\/j.urolonc.2021.10.010","article-title":"Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients","volume":"40","author":"Mertens","year":"2022","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.100997_bib48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jnci\/djn451","article-title":"Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer","volume":"101","author":"Margulis","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"59","key":"10.1016\/j.modpat.2026.100997_bib49","doi-asserted-by":"crossref","first-page":"100614","DOI":"10.18632\/oncotarget.21899","article-title":"Significance of Ki-67 in non-muscle invasive bladder cancer patients: a systematic review and meta-analysis","volume":"8","author":"Ko","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.modpat.2026.100997_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019635","article-title":"Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review","volume":"8","author":"He","year":"2018","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.modpat.2026.100997_bib51","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1158\/1078-0432.CCR-06-2940","article-title":"Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study","volume":"13","author":"Dyrskj\u00f8t","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13000-017-0639-y","article-title":"Level of mitoses in non-muscle invasive papillary urothelial carcinomas (pTa and pT1) at initial bladder biopsy is a simple and powerful predictor of clinical outcome: a multi-center study in South Korea","volume":"12","author":"Kwon","year":"2017","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.modpat.2026.100997_bib53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.humpath.2018.10.008","article-title":"Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system","volume":"84","author":"Zaleski","year":"2019","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/BLC-150012","article-title":"The prognostic value of cell cycle gene expression signatures in muscle invasive, high-grade bladder cancer","volume":"1","author":"Dancik","year":"2015","journal-title":"Bladder Cancer"},{"issue":"3","key":"10.1016\/j.modpat.2026.100997_bib55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","article-title":"Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study","volume":"72","author":"Dyrskj\u00f8t","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.modpat.2026.100997_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12920-015-0101-5","article-title":"Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems","volume":"8","author":"Eriksson","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.modpat.2026.100997_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.110","article-title":"LBA104 first safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)","volume":"34","author":"Vilaseca","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2026.100997_bib59","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"issue":"5S2","key":"10.1016\/j.modpat.2026.100997_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001111604.90306.91.02","article-title":"Final results: Bond-003 cohort C-phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ","volume":"213","author":"Tyson","year":"2025","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0959-8049(93)90579-5","article-title":"Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer","volume":"29A","author":"Lipponen","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.modpat.2026.100997_bib62","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"issue":"10516","key":"10.1016\/j.modpat.2026.100997_bib63","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib64","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2026.100997_bib65","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/2326-6066.CIR-18-0758","article-title":"The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes","volume":"7","author":"Pfannstiel","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-09075-y","article-title":"Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles","volume":"15","author":"Bhinder","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib67","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib68","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41467-024-45714-0","article-title":"Gene-expression-based T-cell-to-stroma enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer","volume":"15","author":"Rijnders","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.modpat.2026.100997_bib69","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:33:02Z","timestamp":1781695982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226000402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0893395226000402"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100997","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100997"}}